Everyone at Leadiant Biosciences works with rare dedication to provide therapies for patients with rare diseases. We partner with patient communities, physicians and researchers worldwide to overcome challenges and be a resource of hope.


Leadiant Biosciences, formerly known as Sigma-Tau Rare Disease, is a research-based global pharmaceutical company dedicated to the development, registration and commercialization of novel and effective therapies that address the needs and improve the quality of life of patients suffering from rare and ultra-rare diseases.

Founded in Italy in 1957, our team combines experience, passion and commitment to delivering treatments to patients who need them. As a company, we focus first and foremost on serving patients. We continually reinvest in our company and technology to enhance our ability to develop the next generation of pharmaceuticals used to meet the challenges of specific diseases.

Leadiant Biosciences S.p.A. operates as a holding for all the business operative Leadiant entities also providing legal, medical, financial and administrative services to the Group. The company will define the targets and strategic directions of the Group, as well as the strategic guidelines and economic-financial drivers.

Leadiant Biosciences operates as Leadiant Biosciences, Inc. in the United States and Canada and as Leadiant Biosciences, Ltd. in the UK (acting as a hub for the international business with direct subsidiaries in Germany and France) and a distribution network in Europe and the rest of the world.